問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



China Medical University Hospital

Link to Hospital │ Link to Clinical Trial Center

  • 2,076

    Total Beds

  • 884

    Total Doctors

  • ctcadm.cmuh@gmail.com
  • Clinical Trial Center
  • 04-22052121#1471~1485
  • 404Taichung CityTaichung NorthNo. 2, Yude Rd., North Dist., Taichung City 404332, Taiwan (R.O.C.)

Recruiting Trial

681Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

1712Cases

2024-06-01 - 2027-12-31

Phase I

Active
A Phase 1, First-in-Human, Open-label, Doseescalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141 in Subjects With Advanced Solid Tumors

  • Condition/Disease

    Metastatic Solid Tumor

  • Test Drug

    Injectable

Participate Sites
3Sites

Recruiting3Sites

2024-06-28 - 2028-03-31

Phase III

A Phase 3 Open-label, Randomized Controlled Study to Evaluate the Efficacy and Safety of Petosemtamab Compared With Investigator's Choice Monotherapy Treatment in Previously Treated Patients With Incurable, Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma

  • Condition/Disease

    Head and Neck Squamous Cell Carcinoma

  • Test Drug

    Intravenous infusion

Participate Sites
8Sites

Not yet recruiting3Sites

Recruiting5Sites

2024-05-17 - 2030-12-31

Phase I/II

Active
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

  • Condition/Disease

    Colorectal Cancer

  • Test Drug

    Injectables Injectables Injectables Injectables Injectables

Participate Sites
5Sites

Recruiting5Sites

2024-05-21 - 2029-02-22

Phase III

Active
A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)

  • Condition/Disease

    Small Cell Lung Cancer

  • Test Drug

    Freeze-dried crystal injection Freeze-dried crystal injection Freeze-crystal injection Freeze-crystal powder for injection

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

2024-06-01 - 2030-12-31

Phase II/III

Active
A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

  • Condition/Disease

    Metastatic Urothelial Cancer

  • Test Drug

    Injectable frozen powder

Participate Sites
6Sites

Recruiting6Sites

2024-06-30 - 2029-06-30

Phase II

Active
Phase II Study of Tislelizumab Combined With Induction Chemoradiotherapy and Subsequent Conversion Surgery for Locally Advanced Unresectable ESCC

  • Condition/Disease

    Esophageal Squamous Cell Carcinoma (ESCC)

  • Test Drug

    Injectable

Participate Sites
8Sites

Recruiting8Sites

2024-07-01 - 2027-11-28

Phase III

Active
An Open-label Extension Trial of the Long-term Safety and Efficacy of BI 1015550 Taken Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF) (FIBRONEER™-ON)

  • Condition/Disease

    Idiopathic Pulmonary Fibrosis

  • Test Drug

    Tablets

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

2024-08-01 - 2029-12-31

Others

Active
A Multi-center, Prospective Study to Observe the Safety, Tolerability, and Efficacy of Remodulin® in Patients With Pulmonary Arterial Hypertension

  • Condition/Disease

    Pulmonary Arterial Hypertension

  • Test Drug

    Active pharmaceutical ingredient solution

Participate Sites
9Sites

Recruiting9Sites

2024-07-31 - 2031-12-31

Phase III

Active
A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)

  • Condition/Disease

    Advanced Breast Cancer

  • Test Drug

    Tablets

Participate Sites
7Sites

Recruiting7Sites

2024-09-01 - 2038-12-31

Phase III

Active
A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)

  • Condition/Disease

    Carcinoma, Non-Small-Cell Lung

  • Test Drug

    Injectables

Participate Sites
9Sites

Recruiting9Sites

1 2 3 4 5 172
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB